CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Intranasal Sufentanil for Acute Pain: Clinical Effectiveness and Guidelines

Last updated: December 6, 2017
Project Number: RB1167-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of intranasal sufentanil for acute pain in adults?
  2. What are the evidence-based guidelines regarding the use of intranasal opioids for acute pain in adults?

Key Message

Three evidence-based guidelines were identified regarding the use of intranasal opioids for acute pain in adults.